What should be included in patient education about occipital nerve stimulation?

Updated: Oct 11, 2018
  • Author: Antonios Mammis, MD; Chief Editor: Jonathan P Miller, MD  more...
  • Print
Answer

Occipital nerve stimulation (ONS) for headache and craniofacial pain is not FDA-approved and thus represents an off-label use of this technology. Insurance companies may or may not cover the cost of occipital nerve stimulation placement, and patients are encouraged to contact their insurances to see if they qualify as candidates and if insurance will cover it.

Patients who are interested in participating in one of several clinical trials are referred to ClinicalTrials.gov.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!